Serglycin is secreted in elevated levels in cancer cells mutated in KRAS or HER1/EGFR, the fact that may suggest an implication of EGFR-RAS pathway in the biosynthesis and more importantly in secretion of serglycin. This evidence concerns the gene EGFR and cancer.